@article{d99c083a604c472a8fa18082eb5d0c4a,
title = "Prediagnostic antibody responses to fusobacterium nucleatum proteins are not associated with risk of colorectal cancer in a large U.S. Consortium",
abstract = "Background: The association between prediagnostic antibody responses to Fusobacterium nucleatum (F. nucleatum) and subsequent risk of colorectal cancer is not established. Methods: We conducted a nested case-control study of 8,126 participants in a consortium of 10 prospective cohorts in the United States. Results: Higher seroprevalence of any F. nucleatum antibody was observed among non-White participants (51.1%) compared with White participants (31.2%). We did not find any statistically significant association between seropositivity to any of the eight F. nucleatum proteins and colorectal cancer risk. Conclusions: Prediagnostic antibody responses to F. nucleatum proteins were not associated with the risk of colorectal cancer. Impact: Future studies may consider a more specific detection of the immunoglobulin isotypes or focus on examining F. nucleatum in stool or tissue samples.",
author = "Lo, {Chun Han} and Blot, {William J.} and Teras, {Lauren R.} and Kala Visvanathan and {Le Marchand}, Loic and Haiman, {Christopher A.} and Yu Chen and Sesso, {Howard D.} and Sylvia Wassertheil-Smoller and Tinker, {Lesley F.} and Peek, {Richard M.} and Potter, {John D.} and Cover, {Timothy L.} and Anne Zeleniuch-Jacquotte and Berndt, {Sonja I.} and Tim Waterboer and Meira Epplein and Julia Butt and Mingyang Song",
note = "Funding Information: W.J. Blot reports grants from NIH during the conduct of the study. L. Le Marchand reports grants from NCI during the conduct of the study. L.F. Tinker reports other from NIH during the conduct of the study. T.L. Cover reports grants from NIH and Department of Veterans Affairs during the conduct of the study. A. Zeleniuch-Jacquotte reports grants from NIH/NCI during the conduct of the study. T. Waterboer reports serving on advisory boards for MSD and (Merck) Sharp & Dohme. M. Epplein reports grants from NCI during the conduct of the study. No disclosures were reported by the other authors. Funding Information: CA040360, and R01 HL034595), and the Multiethnic Cohort Study (U01 CA164973 to principal investigator L. Le Marchand). R.M. Peek was supported by the NIH (R01 DK058587 and R01 CA077955). T.L. Cover was supported by the NIH (R01 AI039657, R01 AI118932, and P01 CA116087) and the Department of Veterans Affairs (BX004447). M. Song was supported by the American Cancer Society (MRSG-17-220-01–NEC) and the NIH (R00 CA215314). The Women{\textquoteright}s Health Initiative program was funded by the National Heart, Lung, and Blood Institute through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The development of Helicobacter pylori multiplex serology was funded, in part, by the Funding Information: The Campaign Against Cancer and Stroke thanks the participants and staff for their contributions, as well as the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Department of Health and Mental Hygiene. The authors would like to thank the participants and staff of the Nurses{\textquoteright} Health Study and the Health Professionals Follow-up Study for their valuable contributions, as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II cohort. The authors express sincere appreciation to all Cancer Prevention Study-II participants, and to each member of the study and biospecimen management group. The authors would like to acknowledge the contribution from central cancer registries supported through the Centers for Disease Control and Prevention{\textquoteright}s National Program of Cancer Registries and cancer registries supported by the NCI{\textquoteright}s Surveillance Epidemiology and End Results Program. The NIH funds this consortium (R01 CA190428 to principal investigator M. Epplein), the Southern Community Cohort Study (U01 CA202979 to principal investigator W.J. Blot), the New York University Women{\textquoteright}s Health Study (U01 CA182934 to principal investigator A. Zeleniuch-Jacquotte and P30 CA016087 to principal investigator B.G. Neel), the Nurses{\textquoteright} Health Study/Health Professionals Follow-Up Study (U01 CA167552, P01 CA087969, UM1 CA186107, and UM1 CA167552), the Physicians{\textquoteright} Health Study (R01 CA097193, R01 Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",
year = "2021",
month = jun,
doi = "10.1158/1055-9965.EPI-20-1471",
language = "English (US)",
volume = "30",
pages = "1279--1282",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",
}